Clinical Trial Detail

NCT ID NCT02955940
Title An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib
Recruitment Enrolling by invitation
Gender both
Phase Phase II
Variant Requirements No
Sponsors Incyte Corporation
Indications

Advanced Solid Tumor

Therapies

Ruxolitinib

Capecitabine + Regorafenib

Capecitabine + Regorafenib + Ruxolitinib

Age Groups: senior adult

No variant requirements are available.